EP1049665A1 - Vla-4-antagonisten - Google Patents

Vla-4-antagonisten

Info

Publication number
EP1049665A1
EP1049665A1 EP99908811A EP99908811A EP1049665A1 EP 1049665 A1 EP1049665 A1 EP 1049665A1 EP 99908811 A EP99908811 A EP 99908811A EP 99908811 A EP99908811 A EP 99908811A EP 1049665 A1 EP1049665 A1 EP 1049665A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
substituted
aryl
alkenyl
substituted alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99908811A
Other languages
English (en)
French (fr)
Inventor
Sompong Wattanasin
Peter Josef Von Matt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Publication of EP1049665A1 publication Critical patent/EP1049665A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP99908811A 1998-01-23 1999-01-21 Vla-4-antagonisten Withdrawn EP1049665A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1233698A 1998-01-23 1998-01-23
US11072398P 1998-12-03 1998-12-03
US110723P 1998-12-03
PCT/EP1999/000384 WO1999037605A1 (en) 1998-01-23 1999-01-21 Vla-4 antagonists
US12336 2001-12-12

Publications (1)

Publication Number Publication Date
EP1049665A1 true EP1049665A1 (de) 2000-11-08

Family

ID=26683440

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99908811A Withdrawn EP1049665A1 (de) 1998-01-23 1999-01-21 Vla-4-antagonisten

Country Status (13)

Country Link
EP (1) EP1049665A1 (de)
JP (1) JP4564654B2 (de)
KR (1) KR20010034317A (de)
CN (1) CN1294576A (de)
AU (1) AU746174B2 (de)
BR (1) BR9907733A (de)
CA (1) CA2318639A1 (de)
EE (1) EE200000428A (de)
HU (1) HUP0100336A3 (de)
ID (1) ID26665A (de)
IL (1) IL137329A0 (de)
NO (1) NO20003694L (de)
WO (1) WO1999037605A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2623900A (en) * 1999-01-22 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
JP4754693B2 (ja) 1999-01-22 2011-08-24 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４関連障害を処置するアシル誘導体
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
JP2003516380A (ja) * 1999-12-07 2003-05-13 ノバルティス アクチエンゲゼルシャフト Ｖｌａ−４インテグリンアンタゴニスト
CA2396087A1 (en) 1999-12-28 2001-07-19 Louis Stanley Chupak Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
DE10019755A1 (de) * 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
GB2367816A (en) 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
NZ505363A (en) * 1997-12-23 2005-02-25 Aventis Pharma Ltd Compounds containing substituted {2-[3-methoxy-4-(3-o-tolylureido)phenyl]acetylamino}- groups and pharmaceuticals thereof; useful as inhibitors of alpha4beta1 mediated cell division

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9937605A1 *

Also Published As

Publication number Publication date
NO20003694L (no) 2000-09-20
AU746174B2 (en) 2002-04-18
WO1999037605A1 (en) 1999-07-29
NO20003694D0 (no) 2000-07-19
EE200000428A (et) 2001-12-17
IL137329A0 (en) 2001-07-24
KR20010034317A (ko) 2001-04-25
CA2318639A1 (en) 1999-07-29
CN1294576A (zh) 2001-05-09
BR9907733A (pt) 2000-10-17
JP2002501039A (ja) 2002-01-15
JP4564654B2 (ja) 2010-10-20
ID26665A (id) 2001-01-25
HUP0100336A3 (en) 2002-11-28
HUP0100336A2 (hu) 2001-07-30
AU2829299A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
AU746174B2 (en) VLA-4 antagonists
JP2725690B2 (ja) カルボキシアルキルペプチド誘導体
EP0917462B1 (de) Zelladhäsionsinhibitoren
WO2001068586A2 (en) α4β1 AND α4β7 INTEGRIN INHIBITORS
US6365619B1 (en) Treatment of arteriosclerosis
EP0805796B1 (de) Zelle adhäsion hemmenden verbindungen
EP0991619B1 (de) Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US7034043B2 (en) Cell adhesion inhibitors
US6596687B1 (en) Cell adhesion inhibitors
US20070066533A1 (en) Cell adhesion inhibitors
JPS62230757A (ja) ヒドロキシルアミン誘導体
US20060030553A1 (en) Cell adhesion inhibitors
JP2002501039A5 (de)
US6432923B1 (en) VLA-4 antagonists
MXPA00007186A (en) Vla-4 antagonists
JPS6230762A (ja) 新規５−オキソ−１−イミダゾリジンアセトアミド誘導体
CZ20002704A3 (cs) Antagonisté VLA-4 a farmaceutický prostředek, který je obsahuje
US20020091142A1 (en) Alpha4beta1 and alpha4beta7 integrin inhibitors
JPH024767A (ja) 薬理作用を有するペプチド類
JPH09188631A (ja) Ｆａｓリガンド可溶化抑制薬
WO2001042192A2 (en) Vla-4 integrin antagonists
JPH01110695A (ja) アミノ酸誘導体その製造方法及び血圧降下剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000719;LV PAYMENT 20000719;SI PAYMENT 20000719

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.

Owner name: NOVARTIS AG

17Q First examination report despatched

Effective date: 20020206

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS PHARMA GMBH

Owner name: NOVARTIS AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS PHARMA GMBH

Owner name: NOVARTIS AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030325

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1033825

Country of ref document: HK